Use of amisulpride as an anti-emetic
View Patent ↗Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
1. A method for the prevention and/or treatment of post-operative nausea and vomiting, comprising administering amisulpride at a dose of less than 50 mg to a subject of a surgical procedure and in need of such prevention and/or treatment.
2. The method of claim 1 , wherein the subject is also administered an emetogenic agent.
3. The method of claim 2 , wherein the emetogenic agent is an opiate.
4. The method of claim 2 , wherein the emetogenic agent is morphine.
5. The method of claim 1 , wherein the subject is a human.
6. The method of claim 1 , wherein the amisulpride is in the form of an acceptable pharmaceutical salt.
7. The method of claim 1 , wherein the amisulpride is administered in combination with another anti-emetic drug.
8. The method of claim 7 , wherein the another anti-emetic drug is a 5HT3 antagonist.
9. The method of claim 8 , wherein the 5HT3 antagonist is ondansetron.
10. The method of claim 1 , wherein the amisulpride is administered in combination with dexamethasone.
11. The method of claim 1 , wherein the amisulpride is administered at a dose of 1 mg to 35 mg.
12. The method of claim 1 , wherein the subject has received an anesthetic.
13. The method of claim 1 , wherein the surgical procedure is chosen from procedures of the eye or ear, laparoscopic cholecystectomy, hysterectomy, breast surgery, abdominal surgery, and gynecological surgery.
14. The method of claim 1 , wherein the amisulpride is administered by intravenous injection, intramuscular injection, or subcutaneous injection.
15. The method of claim 1 , wherein the amisulpride is administered orally.
16. The method of claim 1 , wherein the amisulpride is administered sublingually or intranasally.
17. The method of claim 1 , wherein the amisulpride is administered topically.
18. The method of claim 1 , wherein the amisulpride is administered transdermally.
19. The method of claim 1 , wherein the amisulpride is administered rectally.
20. The method of claim 1 , wherein the amisulpride is (S−)-amisulpride.